GANX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-11

• As of March 31, 2026, two clinical studies of GT-02287 have been completed, and one is ongoing. GT-02287 was initially characterized in a first-in-human Phase 1a clinical study to assess the safety, tolerability, pharmacokinetics, and food effect of GT-02287 in healthy participants. The study design…

• was initiated. The purpose of this study was to compare two oral formulations of GT-02287. This study was completed in the third quarter of 2025.

• In March 2025, we enrolled the first participant with Parkinson’s disease in our two-part Phase 1b safety and tolerability study to further evaluate the safety, tolerability and biomarker evidence of activity for GT-02287. In Part 1 of this study, participants dose daily with GT-02287 for 90 days. I…

• We continue to monitor the impacts on our operations and access to financing from; global and worsening macroeconomic conditions, such as the war in Ukraine, the recent conflict in Iran and the Middle East, global geopolitical tension, exchange rate fluctuations, supply chain disruptions, liquidity …

• In January 2026, we released additional biomarker and clinical data from the Phase 1b study of GT-02287 in Parkinson's disease. Participants with elevated baseline cerebrospinal fluid glucosylsphingosine demonstrated a reduction in levels following three months of treatment, and in the efficacy anal…

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• We continue to monitor the impacts on our operations and access to financing, global and worsening macroeconomic conditions, such as the war in Ukraine, the Hamas-Israel conflict, global geopolitical tension, exchange rate fluctuations, supply chain disruptions, liquidity concerns and increases in c…

• In October 2025 we presented early results from its Phase 1b clinical study in patients with Parkinson’s disease at the International Congress of Parkinson’s Disease and Movement Disorders®. GT-02287 was generally well tolerated,

• with no treatment-emergent serious adverse events observed. Additionally, participants in the open label trial appear to be benefitting from stabilization and trending improvements in their MDS-UPDRS scores after 90 days of GT-02287 administration.

• In September 2025 we elected to extend the open label study for an additional 9 months to allow participants interested in remaining on GT-02287 to continue on the study. The majority of participants have elected to remain on the open label extension.

• Since our inception in 2017, we have devoted substantially all of our resources to identify and develop next-generation brain-penetrant allosteric small molecules for the treatment of devastating diseases with high-unmet medical needs using our Magellan™ platform. Our operations have consisted prima…

Text added vs the prior filing · source: 10-Q · 2026-05-11

• ●the impact of other global events, including political instability, natural disaster, events of terrorism and wars, such as the ongoing conflict between Russia and Ukraine and between the United States and Iran and elsewhere in the Middle East;

• ●the impacts of increased trade tariffs, import quotas or other trade restrictions or measures taken by the United States and other countries, including changes in U.S. trade policies that may be made by the presidential administration; and

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• ●the impact of other global events, including political instability, natural disaster, events of terrorism and wars, including the war between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other coun…

• ●the impacts of changes to international trade policy, including tariff and customs regulations; and

Text added vs the prior filing · source: 10-Q · 2026-05-11

• ●the impact of other global events, including political instability, natural disaster, events of terrorism and wars, such as the ongoing conflict between Russia and Ukraine and between the United States and Iran and elsewhere in the Middle East;

• ●the impacts of increased trade tariffs, import quotas or other trade restrictions or measures taken by the United States and other countries, including changes in U.S. trade policies that may be made by the presidential administration; and

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• ●the impact of other global events, including political instability, natural disaster, events of terrorism and wars, including the war between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other coun…

• ●the impacts of changes to international trade policy, including tariff and customs regulations; and

Text added vs the prior filing · source: 10-Q · 2026-05-11

• ●the impact of other global events, including political instability, natural disaster, events of terrorism and wars, such as the ongoing conflict between Russia and Ukraine and between the United States and Iran and elsewhere in the Middle East;

• ●the impacts of increased trade tariffs, import quotas or other trade restrictions or measures taken by the United States and other countries, including changes in U.S. trade policies that may be made by the presidential administration; and

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• ●the impact of other global events, including political instability, natural disaster, events of terrorism and wars, including the war between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other coun…

• ●the impacts of changes to international trade policy, including tariff and customs regulations; and

Text added vs the prior filing · source: 10-Q · 2026-05-11

• ●the impact of other global events, including political instability, natural disaster, events of terrorism and wars, such as the ongoing conflict between Russia and Ukraine and between the United States and Iran and elsewhere in the Middle East;

• ●the impacts of increased trade tariffs, import quotas or other trade restrictions or measures taken by the United States and other countries, including changes in U.S. trade policies that may be made by the presidential administration; and

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• ●the impact of other global events, including political instability, natural disaster, events of terrorism and wars, including the war between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other coun…

• ●the impacts of changes to international trade policy, including tariff and customs regulations; and

Text added vs the prior filing · source: 10-Q · 2026-05-11

• ●the impact of other global events, including political instability, natural disaster, events of terrorism and wars, such as the ongoing conflict between Russia and Ukraine and between the United States and Iran and elsewhere in the Middle East;

• ●the impacts of increased trade tariffs, import quotas or other trade restrictions or measures taken by the United States and other countries, including changes in U.S. trade policies that may be made by the presidential administration; and

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• ●the impact of other global events, including political instability, natural disaster, events of terrorism and wars, including the war between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other coun…

• ●the impacts of changes to international trade policy, including tariff and customs regulations; and